Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab in TMA Associated with a Trigger
NCT04743804Phase 3Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jun 2021
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in thrombotic microangiopathy (TMA) comparing Ravulizumab Arm with Placebo Arm (2 arms). Primary endpoint: Number of Participants With Complete Thrombotic Microangiopathy (TMA) Response at Week 26. Started Jun 2021; status: terminated.
02
Drugs
ravulizumab
03
Conditions
thrombotic microangiopathy (TMA)
Beyond the preview
Go deeper on NCT04743804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04743804.